Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01062256 · ClinicalTrials.gov registry record · NA
Study of Count Coughs in Subjects With Acute Upper Respiratory Tract Infections
A NA study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- NA
- Development phase
- 265
- Enrollment target
NCT01062256 is a NA study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 265 participants.
The verdict
NCT01062256, a NA study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- NA
- Development phase
- 265 participants
- Enrollment target
Study Summary
The objectives of this study are: a) to assess the feasibility and sensitivity of manually count cough bouts over a 4-hour period; b) to assess the effects of buckwheat honey and guaifenesin 400 mg immediate release tablets compared to placebo on the frequency and severity of acute cough due to upper respiratory tract infection and c) to evaluate the correlation between cough bout frequency and subjective assessments of cough severity. The hypotheses to be tested is that 10 ml of buckwheat honey and 400 mg of immediate release guaifenesin will significantly reduce the frequency and severity of cough compared to placebo over a 4-hour evaluation period.
Interventions
- DRUG Placebo
- DRUG Guaifenesin
- OTHER Buckwheat Honey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2010-01 |
| Est. Completion | 2010-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01062256
The ClinicalTrials.gov registry entry for NCT01062256 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 265 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01062256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01062256 about?
NCT01062256 is a clinical study titled "Study of Count Coughs in Subjects With Acute Upper Respiratory Tract Infections". The objectives of this study are: a) to assess the feasibility and sensitivity of manually count cough bouts over a 4-hour period; b) to assess the effects of buckwheat honey and guaifenesin 400 mg immediate release tablets compared to placebo on the frequency and severity of acute cough due to uppe...
What is the current status of trial NCT01062256?
This trial is currently completed. It is a NA study. The enrollment target is 265 participants. The study started on 2010-01. Estimated completion is 2010-02.
What interventions are being tested in trial NCT01062256?
The interventions under investigation include: Placebo (DRUG), Guaifenesin (DRUG), Buckwheat Honey (OTHER).
Who is sponsoring clinical trial NCT01062256?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.